Clinical Director, University of Alabama School of Medicine
La cta ti onExcreti on i n brea s t mi l k unknown/us e ca uti on Brea s t-Feedi ng Cons i dera ti ons Other corti cos teroi ds ha ve been found i n brea s t mi l k; however symptoms diagnosis cheap depakote 500mg amex, i nforma ti on for becl ometha s one i s not a va i l a bl medicine 6469 discount depakote 250mg on-line. Inha l ed corti cos teroi ds a re recommended for the trea tment of a s thma (mos t i nforma ti on a va i l a bl e us i ng budes oni de) whi l e brea s t-feedi ng symptoms hypoglycemia buy depakote paypal. Risk C: Monitor therapy Nurs i ng: Phys i ca l As s es s ment/Moni tori ngNot to be us ed to trea t s ta tus a s thma ti cus or funga l i nfecti ons of na s a l pa s s a ges. When cha ngi ng from s ys temi c s teroi ds to i nha l a ti ona l s teroi ds, ta per reducti on of s ys temi c medi ca ti on s l owl y. Pa ti ent Educa ti onUs e a s di rected; do not i ncrea s e dos a ge or di s conti nue a bruptl y wi thout cons ul ti ng pres cri ber. Revi ew us e of i nha l er or s pra y wi th pres cri ber or fol l ow pa cka ge i ns ert for di recti ons. Al wa ys ri ns e mouth a nd throa t a fter us e of i nha l er to prevent i nfecti on. If you a re a l s o us i ng a n i nha l ed bronchodi l a tor, wa i t 10 mi nutes before us i ng thi s s teroi d a eros ol. Report a dvers e effects s uch a s s ki n rednes s, ra s h, or i rri ta ti on; pa i n or burni ng of na s a l mucos a; whi the pl a ques i n mouth or fuzzy tongue; unres ol ved hea da che; or wors eni ng of condi ti on or l a ck of i mprovement. Di s ca rd a fter da the ca l cul a ted by pres cri ber; the a mount of medi ca ti on i n ca ni s ter ca nnot be gua ra nteed a fter us i ng the l a bel ed number of a ctua ti ons (s pra ys) even though i t ma y not feel empty. Ri ns e mouth a nd throa t a fter us e to reduce a fterta s the a nd prevent ca ndi di a s i s. Denta l Hea l th: Effects on Denta l Trea tmentKey a dvers e event(s) rel a ted to denta l trea tment: Ora l ca ndi di a s i s, xeros tomi a (norma l s a l i va ry fl ow res umes upon di s conti nua ti on), na s a l drynes s, a nd dry throa t. Loca l i zed i nfecti ons wi th Candida albicans or Aspergillus niger occur frequentl y i n the mouth a nd pha rynx wi th repeti ti ve us e of a n ora l i nha l er; ma y requi re trea tment wi th a ppropri a the a nti funga l thera py or di s conti nua nce of i nha l er us. Expert Pa nel Report: Gui del i nes for the Di a gnos i s a nd Ma na gement of As thma Upda the on Sel ected Topi cs -2002," J Allergy Clin Immunol, 2002, 110(5 Suppl):141-219. Admi ni s tra ti on: OtherPri or to recta l i ns erti on, the fi nger a nd s uppos i tory s houl d be moi s tened. Pregna ncy Ri s k Fa ctorC Pregna ncy Cons i dera ti ons Reproducti on s tudi es ha ve not been conducted wi th thi s product. Refer to Atropi ne a nd Morphi ne Sul fa the monogra phs for a ddi ti ona l i nforma ti on. La cta ti onExcreti on i n brea s t mi l k unknown/us e ca uti on Brea s t-Feedi ng Cons i dera ti ons It i s not known i f/how much morphi ne or a tropi ne ma y be found i n brea s t mi l k fol l owi ng recta l a dmi ni s tra ti on of thi s product. Ca rdi ova s cul a r: Pa l pi ta ti on Centra l nervous s ys tem: Di zzi nes s, drows i nes s Derma tol ogi c: Pruri tus, urti ca ri a Ga s troi ntes ti na l: Cons ti pa ti on, na us ea, vomi ti ng, xeros tomi a Geni touri na ry: Uri na ry retenti on Ocul a r: Bl urred vi s i on, photophobi a Drug Intera cti ons Acetyl chol i nes tera s e Inhi bi tors (Centra l): Anti chol i nergi cs ma y di mi ni s h the thera peuti c effect of Acetyl chol i nes tera s e Inhi bi tors (Centra l). Nurs i ng: Phys i ca l As s es s ment/Moni tori ngAs s es s other medi ca ti ons pa ti ent ma y be ta ki ng for a ddi ti ve or a dvers e i ntera cti ons. Moni tor thera peuti c effecti venes s, s i gns of overdos e, a nd a dvers e effects a t begi nni ng of thera py a nd a t regul a r i nterva l s wi th l ong-term us. As s es s knowl edge/tea ch pa ti ent a ppropri a the us e i f s el f-a dmi ni s tered. Ma y ca us e hypotens i on, di zzi nes s, or drows i nes s; us e ca uti on when dri vi ng, cl i mbi ng s ta i rs, or cha ngi ng pos i ti on (ri s i ng from s i tti ng or l yi ng to s ta ndi ng) or when enga gi ng i n ta s ks requi ri ng a l ertnes s (unti l res pons e to drug i s known); dry mouth or throa t (frequent mouth ca re, frequent s i ps of fl ui ds, chewi ng gum, or s ucki ng l ozenges ma y hel p); cons ti pa ti on (i ncrea s ed exerci s e, fl ui ds, frui t, or fi ber ma y hel p; i f unres ol ved, cons ul t pres cri ber a bout us e of s tool s ofteners); photos ens i ti vi ty (us e s uns creen, wea r protecti ve cl othi ng a nd eyewea r, a nd a voi d di rect s unl i ght); or decrea s ed pers pi ra ti on (a voi d extremes i n tempera ture or exces s i ve a cti vi ty i n hot envi ronments). Report ches t pa i n or pa l pi ta ti ons; pers i s tent di zzi nes s; cha nges i n menta ti on; cha nges i n ga i t; bl urred vi s i on; s hortnes s of brea th or res pi ra tory di ffi cul ty.
Ha ve pa ti ent l i e down a nd a dmi ni s ter by deep SubQ i njecti on us i ng a fi ne needl e (25- to 26-ga uge) treatment urinary incontinence buy 250 mg depakote mastercard. Contra i ndi ca ti ons Hypers ens i ti vi ty to da na pa roi d or thrombocytopeni a a s s oci a ted wi th a pos i ti ve in vitro tes t for a nti pl a tel et a nti bodi es i n the pres ence of da na pa roi d; hypers ens i ti vi ty to pork products or to s ul fi tes (conta i ns meta bi s ul fi te); pa ti ents wi th a cti ve ma jor bl eedi ng; s evere hemorrha gi c di a thes i s (hemophi l i a treatment 6th feb cheap 500 mg depakote amex, i di opa thi c thrombocytopeni c purpura); not for I medicine keychain buy generic depakote from india. Hepa ri n ca n ca us e hyperka l emi a by a ffecti ng a l dos terone; s i mi l a r rea cti ons coul d occur wi th da na pa roi d. Cons i der ri s k vers us benefi t pri or to neura xi a l a nes thes i a; ri s k i s i ncrea s ed by concomi ta nt a gents whi ch ma y a l ter hemos ta s i s, a s wel l a s tra uma ti c or repea ted epi dura l or s pi na l puncture. Pa ti ent s houl d be obs erved cl os el y for bl eedi ng i f thera py i s a dmi ni s tered duri ng or i mmedi a tel y fol l owi ng di a gnos ti c l umba r puncture, epi dura l a nes thes i a, or s pi na l a nes thes i a. Pregna ncy Ri s k Fa ctorB La cta ti onExcreti on i n brea s t mi l k unknown/compa ti bl e Advers e Rea cti ons As wi th a l l a nti coa gul a nts, bl eedi ng i s the ma jor a dvers e effect of da na pa roi d. Ri s k i s i ncrea s ed i n pa ti ents wi th i ndwel l i ng epi dura l ca theters or concomi ta nt us e of other drugs a ffecti ng hemos ta s i s, thrombocytopeni a, hyperka l emi a, wound i nfecti on, s ki n ra s h, a l l ergi c rea cti on. Drug Intera cti ons Anti coa gul a nts: Ma y enha nce the a nti coa gul a nt effect of other Anti coa gul a nts. Risk C: Monitor therapy Drotrecogi n Al fa: Da na pa roi d ma y enha nce the a dvers e/toxi c effect of Drotrecogi n Al fa. As s es s res ul ts of l a bora tory tes ts (s ee a bove), thera peuti c effecti venes s, a nd a dvers e rea cti ons (eg, thrombol yti c rea cti ons - s ee Advers e Rea cti ons a nd Overdos e/Toxi col ogy). Tea ch pa ti ent pos s i bl e s i de effects /a ppropri a the i nterventi ons (eg, bl eedi ng preca uti ons) a nd a dvers e s ymptoms to report (s ee Pa ti ent Educa ti on). You ma y ha ve a tendency to bl eed ea s i l y whi l e ta ki ng thi s drug (brus h teeth wi th s oft brus h, fl os s wi th wa xed fl os s, us e el ectri c ra zor, a voi d s ci s s ors or s ha rp kni ves a nd potenti a l l y ha rmful a cti vi ti es). Report unus ua l fever; unus ua l bl eedi ng or brui s i ng (bl eedi ng gums, nos ebl eed, bl ood i n uri ne, da rk s tool); pa i n i n joi nts or ba ck; s evere hea d pa i n; s ki n ra s h; or rednes s, s wel l i ng, or pa i n a t i njecti on s i te. Denta l Hea l th: Effects on Denta l Trea tmentKey a dvers e event(s) rel a ted to denta l trea tment: As wi th a l l a nti coa gul a nts, bl eedi ng i s the ma jor a dvers e effect of da na pa roi d. Us ua l ma i ntena nce dos e: 800 mg/da y i n 2 di vi ded dos es to a chi eve a menorrhea a nd ra pi d res pons e to pa i nful s ymptoms. Fibrocystic breast disease (females): Ora l: Ra nge: 100-400 mg/da y i n 2 di vi ded dos es Hereditary angioedema (males/females): Ora l: Ini ti a l: 200 mg 2-3 ti mes /da y; a fter fa vora bl e res pons e, decrea s e the dos a ge by 50% or l es s a t i nterva l s of 1-3 months or l onger i f the frequency of a tta cks di cta tes. Boxed Warning]: Peliosis hepatis and benign hepatic adenoma have been reported with long-term use (ma y be compl i ca ted by a cute i ntra -a bdomi na l hemorrha ge). Boxed Warning]: May cause benign intracranial hypertension (pseudotumor cerebri); moni tor for hea da che, na us ea /vomi ti ng, vi s ua l di s turba nces a nd/or pa pi l l edema. Boxed Warning]: Thromboembolism, thrombotic, and thrombophlebitic events have been reported (including lifethreatening or fatal strokes).
Cheap depakote 250 mg on-line. AIDS कैसे होता है और इसके लक्षण क्या हैं //Symptoms & Prevention in Hindi.
Moni tori ng: La b Tes ts Seri a l hepa ti c a nd rena l functi on tes ts (i n pa ti ents wi th i mpa i rment) Pa ti ent Educa ti onSee i ndi vi dua l a gents for As pi ri n medicine bow generic 250mg depakote with visa, Ca ffei ne nature medicine discount depakote 500 mg visa, a nd Codei ne symptoms 5 days after iui order depakote 250 mg with visa. Ca ps ul e: Buta l bi ta l 50 mg, a s pi ri n 325 mg, ca ffei ne 40 mg, a nd codei ne phos pha the 30 mg As comp wi th Codei ne, Fi ori na l wi th Codei ne: Buta l bi ta l 50 mg, a s pi ri n 325 mg, ca ffei ne 40 mg, a nd codei ne phos pha the 30 mg [ma y conta i n benzyl a l cohol] Generi c Ava i l a bl eYes Pri ci ng: U. The combi na ti on product i s for the trea tment of tens i on hea da che, however, the rol e of ea ch component i n the rel i ef of s ymptoms i s not compl etel y unders tood. Bi oa va i l a bi l i ty of the combi na ti on i s i denti ca l to thei r bi oa va i l a bi l i ty when codei ne i s a dmi ni s tered s epa ra tel y from buta l bi ta l, a s pi ri n, a nd ca ffei ne. Rel a ted Informa ti on As pi ri n Ca ffei ne Codei ne Denta l Hea l th Profes s i ona l Cons i dera ti ons There i s no s ci enti fi c evi dence to wa rra nt di s conti nua nce of a s pi ri n pri or to denta l s urgery. Bra nd Na mes Fi ori na l Ca na di a n Bra nd Na mes Fi ori na l Pha rma col ogi c Ca tegoryBa rbi tura the Us e: La bel ed Indi ca ti ons Rel i ef of the s ymptoma ti c compl ex of tens i on or mus cl e contra cti on hea da che Dos i ng: Adul ts Tens i on or mus cl e contra cti on hea da che: Ora l: 1-2 ta bl ets or ca ps ul es every 4 hours; not to exceed 6 ta bl ets or ca ps ul es /da y Dos i ng: El derl yNot recommended for us e i n the el derl y. Risk C: Monitor therapy Aceta mi nophen: Ba rbi tura tes ma y i ncrea s e the meta bol i s m of Aceta mi nophen. Risk C: Monitor therapy Anti depres s a nts (Serotoni n/Norepi nephri ne Reupta ke Inhi bi tor): Ma y enha nce the a nti pl a tel et effect of As pi ri n. Risk D: Consider therapy modification Ca l ci um Cha nnel Bl ockers (Nondi hydropyri di ne): Ma y enha nce the a nti coa gul a nt effect of Sa l i cyl a tes. Risk D: Consider therapy modification Etopos i de: Ba rbi tura tes ma y i ncrea s e the meta bol i s m of Etopos i de. Risk D: Consider therapy modification Gi nkgo Bi l oba: Ma y enha nce the a nti pl a tel et effect of Sa l i cyl a tes. Risk C: Monitor therapy Ora l Contra cepti ve (Es trogens): Ba rbi tura tes ma y di mi ni s h the thera peuti c effect of Ora l Contra cepti ve (Es trogens). Risk D: Consider therapy modification Pentos a n Pol ys ul fa the Sodi um: Ma y enha nce the a dvers e/toxi c effect of Anti pl a tel et Agents. Pri mi done i s converted to phenoba rbi ta l, a nd thus becomes a ddi ti ve wi th exi s ti ng ba rbi tura the thera py. Risk C: Monitor therapy Pyri doxi ne: Ma y i ncrea s e the meta bol i s m of Ba rbi tura tes. Risk D: Consider therapy modification Uri cos uri c Agents: Sa l i cyl a tes ma y di mi ni s h the thera peuti c effect of Uri cos uri c Agents. Nurs i ng: Phys i ca l As s es s ment/Moni tori ngSee i ndi vi dua l a gents for As pi ri n a nd Ca ffei ne. Ca ps ul e: Buta l bi ta l 50 mg, a s pi ri n 325 mg, a nd ca ffei ne 40 mg Fi ori na l : Buta l bi ta l 50 mg, a s pi ri n 325 mg, a nd ca ffei ne 40 mg Ta bl et: Buta l bi ta l 50 mg, a s pi ri n 325 mg, a nd ca ffei ne 40 mg Generi c Ava i l a bl eYes Pri ci ng: U. Pa ti ents ta ki ng one a s pi ri n ta bl et da i l y a s a n a nti thromboti c a nd who requi re denta l s urgery s houl d be gi ven s peci a l cons i dera ti on i n cons ul ta ti on wi th the phys i ci a n before remova l of the a s pi ri n rel a ti ve to preventi on of pos topera ti ve bl eedi ng. La cta ti onExcreti on i n brea s t mi l k unknown/us e ca uti on Advers e Rea cti ons >1%: Derma tol ogi c: Burni ng, conta ct derma ti ti s, erythema, i rri ta ti on, pruri tus, s ti ngi ng Drug Intera cti ons There a re no known s i gni fi ca nt i ntera cti ons. Bra nd Na mes Gyna zol e-1 Ca na di a n Bra nd Na mes Fems ta t One; Gyna zol e-1 Pha rma col ogi c Ca tegoryAnti funga l Agent, Va gi na l Us e: La bel ed Indi ca ti ons Loca l trea tment of vul vova gi na l ca ndi di a s i s Dos i ng: Adul ts Vul vova gi na l ca ndi di a s i s: Intra va gi na l: Gynazole-1: Ins ert 1 a ppl i ca torful (5 g) i ntra va gi na l l y a s a s i ngl e dos e; trea tment ma y need to be extended for up to 6 da ys i n pregna nt women (us e i n pregna ncy duri ng 2nd or 3rd tri mes ter onl y) Dos i ng: El derl yRefer to a dul t dos i ng.
Pregna ncy Ri s k Fa ctorB Pregna ncy Cons i dera ti ons Ani ma l reproducti on s tudi es ha ve not demons tra ted a dvers e effects symptoms low blood sugar discount depakote 500 mg with visa. Women of chi l dbea ri ng potenti a l a re encoura ged to enrol l i n Fa bry regi s try 4 medications list at walmart purchase depakote 250mg otc. La cta ti onExcreti on i n brea s t mi l k unknown/us e ca uti on Brea s t-Feedi ng Cons i dera ti ons Nurs i ng mothers a re encoura ged to enrol l i n Fa bry regi s try medications zolpidem order depakote 250 mg online. Advers e Rea cti ons Note: the mos t common a nd s eri ous a dvers e rea cti ons a re i nfus i on rea cti ons (s ymptoms ma y i ncl ude fever, ta chyca rdi a, hypertens i on, throa t ti ghtnes s, dys pnea, chi l l s, a bdomi na l pa i n, pruri tus, urti ca ri a, vomi ti ng). Moni tori ng Pa ra meters Devel opment of IgG or IgE a nti bodi es i n pa ti ents wi th s us pected a l l ergi c rea cti ons (tes t a va i l a bl e from ma nufa cturer). Nurs i ng: Phys i ca l As s es s ment/Moni tori ngAs s es s pa ti ent for previ ous experi ence wi th enzyme repl a cement thera py pri or to begi nni ng thera py. Note s peci fi c a dmi ni s tra ti on deta i l s rel a ted to i ni ti a l i nfus i on ra the a nd s ubs equent ra tes. Pa ti ent mus t be moni tored cl os el y for i nfus i on rea cti ons (fever, chi l l s, dys pnea, ta chyca rdi a, hypertens i on, pruri tus, vomi ti ng) duri ng a nd fol l owi ng i nfus i on; medi ca ti on/equi pment for trea ti ng rea cti ons s houl d be rea di l y a va i l a bl. Moni tori ng: La b Tes ts Devel opment of IgG or IgE a nti bodi es i n pa ti ents wi th s us pected a l l ergi c rea cti ons (tes t a va i l a bl e from ma nufa cturer). You ma y experi ence a bdomi na l di s comfort or vomi ti ng (s ma l l, frequent mea l s a nd good mouth ca re ma y hel p); hea da che, fa ti gue, or di zzi nes s (us e ca uti on when dri vi ng or enga gi ng i n ta s ks tha t requi re a l ertnes s unti l res pons e to medi ca ti on i s known); or l i mb, ba ck, or mus cl e pa i n (cons ul t pres cri ber for a ppropri a the a na l ges i a). The compounds ma y a ccumul a the (over ma ny yea rs) wi thi n the ti s s ues of pa ti ents wi th Fa bry di s ea s e, l ea di ng to rena l a nd ca rdi ova s cul a r compl i ca ti ons. It i s bel i eved tha t l ong-term enzyme repl a cement ma y reduce cl i ni ca l ma ni fes ta ti ons of rena l fa i l ure, ca rdi omyopa thy, a nd s troke. However, the rel a ti ons hi p to a reducti on i n cl i ni ca l ma ni fes ta ti ons ha s not been es ta bl i s hed. Bra nd Na mes Al benza Pha rma col ogi c Ca tegoryAnthel mi nti c Us e: La bel ed Indi ca ti ons Trea tment of pa renchyma l neurocys ti cercos i s ca us ed by Taenia solium a nd cys ti c hyda ti d di s ea s e of the l i ver, l ung, a nd peri toneum ca us ed by Echinococcus granulosus Us e: Unl a bel ed/Inves ti ga ti ona l Al benda zol e ha s a cti vi ty a ga i ns t Ascaris lumbricoides (roundworm); Ancylostoma caninum; Ancylostoma duodenale a nd Necator americanus (hookworms); cuta neous l a rva mi gra ns; Enterobius vermicularis (pi nworm); Gnathostoma spinigerum; Gongylonema s p; Mansonella perstans (fi l a ri a s i s); Opisthorchis sinensis (l i ver fl uke); vi s cera l l a rva mi gra ns (toxoca ri a s i s); a cti vi ty ha s a l s o been s hown a ga i ns t the l i ver fl uke Clonorchis sinensis, Giardia lamblia, Cysticercus cellulosae, a nd Echinococcus multilocularis. Al benda zol e ha s a l s o been us ed for the trea tment of i ntes ti na l mi cros pori di os i s (Encephalitozoon intestinalis), di s s emi na ted mi cros pori di os i s (E. Dos i ng: Adul ts Neurocysticercosis: Ora l: <60 kg: 15 mg/kg/da y i n 2 di vi ded dos es (ma xi mum: 800 mg/da y) for 8-30 da ys 60 kg: 800 mg/da y i n 2 di vi ded dos es for 8-30 da ys Note: Gi ve concurrent a nti convul s a nt a nd s teroi d thera py duri ng fi rs t week. Hydatid: Ora l: <60 kg: 15 mg/kg/da y i n 2 di vi ded dos es (ma xi mum: 800 mg/da y) 60 kg: 800 mg/da y i n 2 di vi ded dos es Note: Admi ni s ter dos e for three 28-da y cycl es wi th a 14-da y drug-free i nterva l i n between. Ancylostoma caninum, Ascaris lumbricoides(roundworm), Ancylostoma duodenale (hookworm), and Necator americanus(hookworm) (unlabeled use): Ora l: 400 mg a s a s i ngl e dos e Clonorchis sinensis(Chinese liver fluke) (unlabeled use): Ora l: 10 mg/kg for 7 da ys Cutaneous larva migrans (unlabeled use): Ora l: 400 mg once da i l y for 3 da ys Enterobius vermicularis(pinworm) (unlabeled use): Ora l: 400 mg a s a s i ngl e dos e; ma y repea t i n 2 weeks Gnathostoma spinigerum (unlabeled use): Ora l: 800 mg/da y i n 2 di vi ded dos es for 21 da ys Gongylonemiasis (unlabeled use): Ora l: 10 mg/kg/da y for 3 da ys Mansonella perstans(unlabeled use): Ora l: 800 mg/da y i n 2 di vi ded dos es for 10 da ys Visceral larva migrans (toxocariasis) (unlabeled use): Ora l: 800 mg/da y i n 2 di vi ded dos es for 5 da ys Cysticercus cellulosae(unlabeled use): Ora l: 800 mg/da y i n 2 di vi ded dos es for 8-30 da ys; ma y be repea ted a s neces s a ry Disseminated microsporidiosis (unlabeled use): Ora l: 800 mg/da y i n 2 di vi ded dos es Echinococcus granulosus(tapeworm) (unlabeled use): Ora l: 800 mg/da y i n 2 di vi ded dos es for 1-6 months Intestinal microsporidiosis (unlabeled use): Ora l: 800 mg/da y i n 2 di vi ded dos es for 21 da ys Ocular microsporidiosis (unlabeled use): Ora l: 800 mg/da y i n 2 di vi ded dos es, i n combi na ti on wi th fuma gi l l i n Dos i ng: El derl yRefer to a dul t dos i ng. Cysticercus cellulosae(unlabeled use): Ora l: 15 mg/kg/da y (ma xi mum: 800 mg/da y) i n 2 di vi ded dos es for 8-30 da ys; ma y be repea ted a s neces s a ry Echinococcus granulosus(tapeworm) (unlabeled use): Ora l: 15 mg/kg/da y (ma xi mum: 800 mg) di vi ded twi ce da i l y for 1-6 months For the following unlabeled uses, refer to adult dosing: Ancylostoma caninum, Ascaris lumbricoides (roundworm), Ancylostoma duodenale (hookworm), Clonorchis sinensis, (Chi nes e l i ver fl uke), cuta neous l a rva mi gra ns, Enterobius vermicularis (pi nworm), Gnathostoma spinigerum, gongyl onemi a s i s, Mansonella perstans, Necator americanus (hookworm), vi s cera l l a rva mi gra ns (toxoca ri a s i s) Admi ni s tra ti on: Ora l Shoul d be a dmi ni s tered wi th a hi gh-fa t mea l. Admi ni s ter a nti convul s a nt a nd s teroi d thera py duri ng fi rs t week of neurocys ti cercos i s thera py. If pa ti ents ha ve di ffi cul ty s wa l l owi ng, ta bl ets ma y be crus hed or chewed, then s wa l l owed wi th a dri nk of wa ter. Di s conti nue thera py i n a l l pa ti ents who devel op cl i ni ca l l y s i gni fi ca nt decrea s es i n bl ood cel l counts.
